tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

NAMS Stock Latest News

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press ReleasesNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
13d ago
NAMS
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
PremiumPress Releases
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September
21d ago
NAMS
NewAmsterdam Pharma initiated with a Buy at Needham
PremiumThe Fly
NewAmsterdam Pharma initiated with a Buy at Needham
23d ago
NAMS
NewAmsterdam Pharma management to meet with Jefferies
PremiumThe Fly
NewAmsterdam Pharma management to meet with Jefferies
24d ago
NAMS
NewAmsterdam Pharma reports Q2 EPS (41c), consensus (58c)
PremiumThe Fly
NewAmsterdam Pharma reports Q2 EPS (41c), consensus (58c)
1M ago
NAMS
NAMS Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsNAMS Upcoming Earnings Report: What to Expect?
2M ago
NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2M ago
NAMS
NewAmsterdam Pharma’s Successful Obicetrapib Phase 3 Trial
Premium
Company Announcements
NewAmsterdam Pharma’s Successful Obicetrapib Phase 3 Trial
2M ago
8K
NAMS
NewAmsterdam Pharma announces data from Phase 3 BROOKLYN trial
PremiumThe Fly
NewAmsterdam Pharma announces data from Phase 3 BROOKLYN trial
2M ago
NAMS
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
PremiumPress Releases
NewAmsterdam Pharma to Announce Topline Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia on Monday, July 29, 2024
2M ago
NAMS
NewAmsterdam Pharma Board Reshuffles, Welcomes Industry Experts
PremiumCompany Announcements
NewAmsterdam Pharma Board Reshuffles, Welcomes Industry Experts
2M ago
8K
NAMS
NewAmsterdam Pharma appoints McKenna, Joustra to board of directors
PremiumThe Fly
NewAmsterdam Pharma appoints McKenna, Joustra to board of directors
2M ago
APGE
NAMS
NewAmsterdam Pharma completes enrollment for Phase 3 TANDEM trial
PremiumThe FlyNewAmsterdam Pharma completes enrollment for Phase 3 TANDEM trial
2M ago
NAMS
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
Premium
Press Releases
NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib plus Ezetimibe in Patients with HeFH and/or ASCVD or ASCVD Risk Factors
2M ago
NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3M ago
NAMS
NewAmsterdam Pharma Secures Key Patent, Eyes Commercialization
PremiumCompany Announcements
NewAmsterdam Pharma Secures Key Patent, Eyes Commercialization
3M ago
8K
NAMS
NewAmsterdam Pharma announces USPTO issued patent for Obicetrapib
PremiumThe Fly
NewAmsterdam Pharma announces USPTO issued patent for Obicetrapib
3M ago
NAMS
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
3M ago
NAMS
Jefferies sees ‘key nuance’ in comparing NewAmsterdam to AstraZeneca data
PremiumThe Fly
Jefferies sees ‘key nuance’ in comparing NewAmsterdam to AstraZeneca data
4M ago
AZN
NAMS
NewAmsterdam Pharma initiated with a Buy at TD Cowen
PremiumThe FlyNewAmsterdam Pharma initiated with a Buy at TD Cowen
4M ago
NAMS
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
Premium
Press Releases
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
4M ago
NAMS
NewAmsterdam Pharma reports Q1 EPS ($1.06), consensus (53c)
Premium
The Fly
NewAmsterdam Pharma reports Q1 EPS ($1.06), consensus (53c)
4M ago
NAMS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >